JP2021521828A5 - - Google Patents

Info

Publication number
JP2021521828A5
JP2021521828A5 JP2020559481A JP2020559481A JP2021521828A5 JP 2021521828 A5 JP2021521828 A5 JP 2021521828A5 JP 2020559481 A JP2020559481 A JP 2020559481A JP 2020559481 A JP2020559481 A JP 2020559481A JP 2021521828 A5 JP2021521828 A5 JP 2021521828A5
Authority
JP
Japan
Prior art keywords
cells
salt
hydroxycitric acid
cultured
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020559481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521828A (ja
JP7342030B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028513 external-priority patent/WO2019209715A1/en
Publication of JP2021521828A publication Critical patent/JP2021521828A/ja
Publication of JP2021521828A5 publication Critical patent/JP2021521828A5/ja
Application granted granted Critical
Publication of JP7342030B2 publication Critical patent/JP7342030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559481A 2018-04-24 2019-04-22 ヒドロキシクエン酸および/またはその塩を使用してt細胞集団を産生する方法 Active JP7342030B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661941P 2018-04-24 2018-04-24
US62/661,941 2018-04-24
PCT/US2019/028513 WO2019209715A1 (en) 2018-04-24 2019-04-22 Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof

Publications (3)

Publication Number Publication Date
JP2021521828A JP2021521828A (ja) 2021-08-30
JP2021521828A5 true JP2021521828A5 (enExample) 2022-05-02
JP7342030B2 JP7342030B2 (ja) 2023-09-11

Family

ID=66641471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559481A Active JP7342030B2 (ja) 2018-04-24 2019-04-22 ヒドロキシクエン酸および/またはその塩を使用してt細胞集団を産生する方法

Country Status (7)

Country Link
US (2) US12415845B2 (enExample)
EP (1) EP3784774B1 (enExample)
JP (1) JP7342030B2 (enExample)
CN (2) CN112262212B (enExample)
AU (1) AU2019260656B2 (enExample)
CA (1) CA3097858A1 (enExample)
WO (1) WO2019209715A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3959305A1 (en) * 2019-04-26 2022-03-02 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
WO2021222479A1 (en) * 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
EP4178590A4 (en) * 2020-07-09 2024-09-25 The Board of Trustees of the Leland Stanford Junior University MULTIPARALLEL ANALYSIS OF T-CELL THERAPIES

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
CA2674445C (en) 2007-01-12 2016-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
US8785601B2 (en) 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−2キメラ抗原受容体及び癌の治療のためのその使用
US9345748B2 (en) 2010-09-21 2016-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SSX-2 T cell receptors and related materials and methods of use
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
SI2755997T1 (sl) 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
JP6267644B2 (ja) 2011-10-20 2018-01-24 アメリカ合衆国 抗cd22キメラ抗原受容体
CA2868121C (en) 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
ES2835200T3 (es) 2012-05-22 2021-06-22 Us Health Uso médico de células que comprenden receptores de células T anti-NY-ESO-1
US9879065B2 (en) 2012-09-14 2018-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing MHC class II-restricted MAGE-A3
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
CA2936984A1 (en) 2014-01-24 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
CN107075479A (zh) 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞的方法
ES2924709T3 (es) 2014-10-02 2022-10-10 Us Health Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer
US20170312200A1 (en) * 2014-10-29 2017-11-02 Showa Denko K.K. An agent for improving mitochondrial function
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
US20190321314A1 (en) 2016-09-15 2019-10-24 Memorial Sloan Kettering Cancer Center Inhibition of Acetyl-CoA Metabolism for Treatment and Prevention of Immune System Diseases and Disorders

Similar Documents

Publication Publication Date Title
Nallasamy et al. Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis
Nojima et al. In-vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo
JP6022667B2 (ja) 炎症性ヒトTh17細胞の増殖および機能を決定的に調節するICOS
US20210085719A1 (en) Bispecific car t-cells for solid tumor targeting
Terabe et al. Role of IL-13 in regulation of anti-tumor immunity and tumor growth
CN103756964B (zh) 一种高效扩增cd3-cd56+的自然杀伤细胞培养系统的方法
TW202020141A (zh) 一種用於nk細胞體外擴增的培養基體系及nk細胞體外擴增的方法
WO2020057486A1 (zh) 经修饰的t细胞、其制备方法及用途
IL274293B2 (en) Process for generating therapeutic compositions of engineered cells
JP2017533706A5 (enExample)
JP2020534839A5 (enExample)
CN109121413A (zh) 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法
JP2016524914A5 (enExample)
JP2012521215A5 (enExample)
Lv et al. γδT cells, a key subset of T cell for cancer immunotherapy
WO2019206326A1 (zh) 改进的t细胞治疗方法
Huang et al. T cell immune response within B-cell follicles
Xiao et al. Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity
CN101313061A (zh) 扩增双阴性t细胞的方法
Fu et al. Efficacy of human iPSC-derived CAR-NK cells targeting multiple myeloma cells
Koppers et al. Chimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancer
Lin et al. Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy
CN112262212B (zh) 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
Durgin et al. Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence
Amiji et al. Cancer Immunology and Immunotherapy: Volume 1 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy